These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20371747)

  • 1. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
    Moriyama B; Henning SA; Childs R; Holland SM; Anderson VL; Morris JC; Wilson WH; Drusano GL; Walsh TJ
    Ann Pharmacother; 2010 May; 44(5):929-35. PubMed ID: 20371747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.
    Moriyama B; Henning SA; Neuhauser MM; Danner RL; Walsh TJ
    Ann Pharmacother; 2009 Jul; 43(7):1324-37. PubMed ID: 19584386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
    Thabit AK; Hobbs ALV; Guzman OE; Shea KM
    Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
    Gómez-Junyent J; Rigo-Bonnin R; Benavent E; Soldevila L; Padullés A; Cabo X; Tubau F; Ariza J; Murillo O
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):587-599. PubMed ID: 32440843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.
    Heil EL; Lowery AV; Thom KA; Nicolau DP
    Pharmacotherapy; 2015 Jan; 35(1):54-8. PubMed ID: 25556715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
    Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM
    Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
    Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y
    Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients.
    Thompson RZ; Martin CA; Burgess DR; Rutter WC; Burgess DS
    J Cyst Fibros; 2016 Sep; 15(5):660-3. PubMed ID: 27132188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study.
    Almangour TA; Ghonem L; Alassiri D; Aljurbua A; Al Musawa M; Alharbi A; Almuhisen S; Alghaith J; Damfu N; Aljefri D; Alfahad W; Alrasheed M; Khormi Y; Almohaizeie A
    J Infect Chemother; 2024 Oct; 30(10):1008-1014. PubMed ID: 38537776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
    Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
    Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.
    Ferrari F; Lu Q; Girardi C; Petitjean O; Marquette CH; Wallet F; Rouby JJ;
    Intensive Care Med; 2009 Oct; 35(10):1792-800. PubMed ID: 19652947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
    Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
    Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
    Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
    J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
    Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
    Papp-Wallace KM; Zeiser ET; Becka SA; Park S; Wilson BM; Winkler ML; D'Souza R; Singh I; Sutton G; Fouts DE; Chen L; Kreiswirth BN; Ellis-Grosse EJ; Drusano GL; Perlin DS; Bonomo RA
    J Infect Dis; 2019 Jul; 220(4):666-676. PubMed ID: 31099835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.